X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, WMBIO will sponsor the Phase 1 (or Phase 1b) clinical trial for WM-A1-3389, a novel therapeutic antibody for Non-Small Cell Lung Cancer (NSCLC) patients with low or no PD-L1 expression, in combination with KEYTRUDA (pembrolizumab), MSD's anti-PD-1 therapy.
Lead Product(s): WM-A1-3389,Pembrolizumab
Therapeutic Area: Oncology Product Name: WM-A1-3389
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 07, 2023
Details:
Wellmarker has received approval from the Australian Therapeutic Goods Administration (TGA) for a Phase I clinical trial using WM-S1-030, a targeted anti-cancer drug for colorectal cancer and progressive cancer.
Lead Product(s): WM-S1-030
Therapeutic Area: Oncology Product Name: WM-S1-030
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Labcorp Drug Development
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
